Elevated triglyceride levels were found to be independently associated with adverse cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
78% of recently recovered COVID-19 patients had abnormal cardiac magnetic resonance findings.
Both heart failure and coronary heart disease appear to be important underlying conditions in the pathophysiology of cardiorenal syndrome, according to investigators.
Lower baseline eGFR and a history of coronary artery disease may predict the risk for hemodialysis after total artificial heart implantation.
Replacement of energy from animal with plant protein linked to reductions for men, women.
Reductions in risk seen for all-cause, CV mortality and composite of atherosclerotic CV events.
The use of statins appears to benefit patients hospitalized with COVID-19, according to the findings of a retrospective study conducted in Hubei Province, China.
The FDA has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsartan (Entresto; Novartis) in the treatment of heart failure with preserved ejection fraction.
Authors used umbrella review method to explore health outcomes associated with low-dose aspirin.
